Glenmark Pharmaceuticals
CCI approves Nirma’s acquisition of 75% stake in Glenmark Life Sciences
21 Dec 2023
The Competition Commission of India (CCI) has approved acquisition of majority shareholding of Glenmark Life Sciences (GLS) Limited by the Nirma Limited.
US FDA approves Glenmark's oral contraceptives
24 Feb 2016
HC blocks Glenmark from selling US firm’s diabetes drug
20 Mar 2015
A bench of Justices S Ravindra Bhat and Najmi Waziri, while granting the interim injunction, said Merck Sharp and Dohme "has established a prima facie case of patent infringement" by Glenmark
Glenmark recalls anti-ulcer drug in the US over tablet mix-up
19 Apr 2014
Glenmark Pharmaceuticals Ltd is recalling 2,900 bottles of its anti-ulcer drug ranitidine from the US market after a tablet to treat high blood pressure was found in one of the bottles
Delhi HC refuses interim relief to Merck over Glenmark drug
05 Apr 2013
Glenmark said the US drug firm has no patent rights over ‘Sitagliptin Phosphate’, which is used in its anti-diabetes drugs Zita and Zita-Met
Glenmark wins favourable interim order in deal with Napo
14 Jan 2012
In a significant positive for Glenmark Pharmaceuticals Ltd, its US partner in a drug development and marketing agreement, Napo Pharmaceuticals Inc, will not be able to terminate a deal thanks to an arbitration order
Glenmark to market Crofelemer despite Napo nix
15 Dec 2011
Glenmark sells new drug licence to Sanofi for $50 mn
17 May 2011
In addition, Glenmark could receive potential success-based development, regulatory and commercial milestone payments of up to $613 million, subject to the drug getting past the remaining phases of human trials
US FDA approves Glenmark's corticosteroid
10 Aug 2010
Merck settles Zetia patent suit with Glenmark
11 May 2010
Glenmark in $325-million drug deal with Sanofi-Aventis
03 May 2010
Under the terms of the agreement, Glenmark will receive an upfront payment as well as development, regulatory and commercial milestone payments, that could reach a total of $325 million
Glenmark launches two new generics in UK
07 Apr 2010
Featured articles
The remarkable Ratan Tata
By Kiron Kasbekar | 23 Oct 2024
One newspaper report of Ratan Tata’s passing away showed an old photo of him climbing into the cockpit of a Lockheed Martin F-16 fighter.
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation